Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy

被引：0
|
作者：
Mohyuddin, Ghulam Rehman [1 ]
Chakraborty, Rajshekhar [2 ]
Calip, Gregory S. [3 ]
Ascha, Mustafa S. [3 ]
Wang, Xiaoliang [3 ]
Rubinstein, Samuel M. [4 ]
Tuchman, Sascha [4 ]
Costa, Luciano [5 ]
Haaland, Benjamin [6 ]
Giri, Smith [5 ]
Mian, Hira [7 ]
Fonseca, Rafael [8 ]
Sborov, Douglas [1 ]
机构：
[1] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT 84112 USA
[2] Columbia Univ, Dept Hematol, New York, NY USA
[3] Flatiron Hlth, New York, NY USA
[4] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Dept Med, Div Hematol, Chapel Hill, NC USA
[5] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA
[6] Univ Utah, Dept Populat Sci, Salt Lake City, UT USA
[7] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[8] Mayo Clin Arizona, Div Hematol & Oncol, Phoenix, AZ USA
来源：
BLOOD CANCER JOURNAL | 2022年 / 12卷 / 12期
关键词：
D O I：
10.1038/s41408-022-00769-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Myeloma Drug Sensitivity Testing to Optimize Retreatment with Anti-CD38 Monoclonal Antibodies in Daratumumab-Refractory Patients
    De Acha, Olivia Perez
    Idler, Beau M.
    Walker, Zachary J.
    Forsberg, Peter A.
    Mark, Tomer M.
    Sherbenou, Daniel W.
    BLOOD, 2020, 136
  • [32] Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study
    Sunami, Kazutaka
    Fuchida, Shin-ichi
    Suzuki, Kenshi
    Ri, Masaki
    Matsumoto, Morio
    Shimazaki, Chihiro
    Asaoku, Hideki
    Shibayama, Hirohiko
    Ishizawa, Kenichi
    Takamatsu, Hiroyuki
    Ikeda, Takashi
    Maruyama, Dai
    Imada, Kazunori
    Uchiyama, Michihiro
    Kiguchi, Toru
    Iyama, Satoshi
    Murakami, Hirokazu
    Onishi, Reiko
    Tada, Keisuke
    Iida, Shinsuke
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (03) : 442 - 452
  • [33] Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
    Nina Nguyen
    Sana Chaudhry
    Tulasigeri M. Totiger
    Robert Diaz
    Evan Roberts
    Skye Montoya
    Gabriel Pardo
    Alejandro Pardo
    Jumana Afaghani
    Maurizio Affer
    Jacob Jahn
    Terrence Bradley
    Francesco Maura
    Dickran Kazandjian
    Daniel Bilbao
    Jennifer Chapman
    Ola Landgren
    James Hoffman
    Justin Taylor
    npj Precision Oncology, 6
  • [34] Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
    Chaudhry, Sana
    Nguyen, Nina
    Khurana, Rimpi
    Totiger, Tulasigeri M.
    Montoya, Skye
    Afaghani, Jumana
    Bradley, Terrence
    Maura, Francesco
    Kazandjian, Dickran
    Chapman, Jennifer
    Schurer, Stephan
    Landgren, Ola
    Hoffman, James
    Taylor, Justin
    CANCER RESEARCH, 2022, 82 (12)
  • [35] Combination Venetoclax and Selinexor Effective in Relapsed/Refractory Multiple Myeloma with Translocation t(11;14)
    Nguyen, Nina
    Chaudhry, Sana
    Totiger, Tulasigeri M.
    Montoya, Skye
    Afaghani, Jumana
    Bradley, Terrence
    Maura, Francesco
    Kazandjian, Dickran
    Chapman, Jennifer R.
    Landgren, Ola
    Hoffman, James E.
    Taylor, Justin
    BLOOD, 2021, 138
  • [36] Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
    Nguyen, Nina
    Chaudhry, Sana
    Totiger, Tulasigeri M.
    Diaz, Robert
    Roberts, Evan
    Montoya, Skye
    Pardo, Gabriel
    Pardo, Alejandro
    Afaghani, Jumana
    Affer, Maurizio
    Jahn, Jacob
    Bradley, Terrence
    Maura, Francesco
    Kazandjian, Dickran
    Bilbao, Daniel
    Chapman, Jennifer
    Landgren, Ola
    Hoffman, James
    Taylor, Justin
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [37] Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
    Martin, Thomas G.
    Shah, Nina
    Richter, Joshua
    Vesole, David H.
    Wong, Sandy W.
    Huang, Chiung-Yu
    Madduri, Deepu
    Jagannath, Sundar
    Siegel, David S.
    Biran, Noa
    Wolf, Jeffrey L.
    Parekh, Samir
    Cho, Hearn J.
    Munster, Pamela
    Richard, Shambavi
    Ziti-Ljajic, Samira
    Chari, Ajai
    CANCER, 2021, 127 (11) : 1816 - 1826
  • [38] Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma
    Tan, Carlyn Rose Co
    Rueda, Colin
    Shekarkhand, Tala
    Derkach, Andriy
    Korde, Neha
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather Jolie
    Giralt, Sergio
    Usmani, Saad Zafar
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial
    Tian, Ying
    Zhou, Keshu
    Lin, Quande
    Qian, Wenbin
    Yang, Wei
    Sao, Li
    Yuan, Guolin
    Yan, Xiaojing
    Ma, Liangming
    Zhou, Xin
    Liu, Lihong
    Zhu, Fangbing
    Zuo, Xuelan
    Du, Xin
    Ji, Xu
    Zhang, Xuzhao
    Shen, Jing
    Zhou, Hai
    Li, Na
    Chen, Wenming
    BLOOD, 2024, 144 : 4746 - 4747
  • [40] Real-world treatment patterns and clinical outcomes amongst patients with relapsed/refractory multiple myeloma previously treated with lenalidomide and an anti-CD38 monoclonal antibody
    Cowan, Andrew
    Katz, Jessica
    Ho, Carrie
    Gu, Tao
    Marshall, Thomas
    Gu, Fangyi
    Tang, Yuexin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S169 - S169
12345